Soleno Therapeutics Appoints Experienced Eli Lilly Veteran Jennifer Fulk as New CFO
Summary
Soleno Therapeutics announced the appointment of Jennifer Fulk, an experienced finance executive from Eli Lilly and other public companies, as its new Chief Financial Officer, succeeding the retiring James Mackaness.
Key Events
-
New Chief Financial Officer Appointed
Jennifer Fulk, with over two decades of public company experience including 15 years at Eli Lilly, will join as CFO on March 2, 2026.
-
Current CFO Retirement and Transition
James Mackaness will retire by the end of March 2026, with a smooth transition plan including consulting services until December 31, 2026. His departure was not due to any disagreement.
-
Executive Compensation Package
The new CFO's compensation includes an annual base salary of $525,000, a target cash bonus of 45% of base salary, and equity awards totaling 106,860 shares (67,660 stock options and 39,200 restricted stock units).
Analysis
Soleno Therapeutics is strengthening its executive leadership with the appointment of Jennifer Fulk as Chief Financial Officer, effective March 2, 2026. Fulk brings over two decades of public company experience, including 15 years in finance executive roles at Eli Lilly and CFO positions at other publicly traded companies. This strategic hire comes as Soleno Therapeutics has achieved its first profitable year and is successfully commercializing VYKAT XR, indicating a focus on robust financial management and continued growth. The outgoing CFO, James Mackaness, is retiring amicably and will provide consulting services to ensure a smooth transition.
At the time of this filing, SLNO was trading at $41.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $36.67 to $90.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.